Company news
Nuvectis Pharma, Inc. news in 2022
Nuvectis Pharma, Inc.'s news releases, calls and decks from 2022, newest first.
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
November 30, 2022
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
November 7, 2022
Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 17, 2022
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
October 2, 2022
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
September 27, 2022
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
September 12, 2022
Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
September 6, 2022
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
August 4, 2022
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
July 26, 2022
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
June 20, 2022
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
June 12, 2022
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
May 19, 2022
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
May 9, 2022
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
April 12, 2022
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
April 10, 2022
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
March 21, 2022
Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
March 9, 2022
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
March 8, 2022
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
February 21, 2022
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 7, 2022
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 3, 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 27 slides · November 2022
- IPO Roadshow (January 2022)
IPO roadshow · 22 slides · Jan 18, 2022